Who
Sarah B. Noonberg
Director
Company insider
Files Form 4 as: Director, Neurogene; Chief Medical Officer, Metagenomi Therapeutics; Director, Marinus Pharmaceuticals; Director, Protagonist Therapeutics; Chief Medical Officer, Prothena Corporation.
In numbers
- Trades disclosed
- 37
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $222K
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 16 May 2017
- Last trade
- 20 Feb 2026
- Last filed
- 24 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Feb 2026filed 24 Feb 2026 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,050 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,050 at $0.00 | filing |
| 12 Jun 2025filed 13 Jun 2025 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,050 at $0.00 | filing |
| 6 Jun 2025filed 9 Jun 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $9,1685,239 at $1.75 | filing |
| 1 Apr 2025filed 3 Apr 2025 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,000 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | Marinus Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —10,450 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | Marinus Pharmaceuticals | SEC FORM 4 Code A | —2,300 at $0.00 | filing |
| 14 Jun 2024filed 17 Jun 2024 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,700 at $0.00 | filing |
| 1 Apr 2024filed 3 Apr 2024 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —242,875 at $0.00 | filing |
| 1 Apr 2024filed 3 Apr 2024 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code A | —57,763 at $0.00 | filing |
| 18 Jan 2024filed 19 Jan 2024 | Marinus Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —20,900 at $0.00 | filing |
| 18 Jan 2024filed 19 Jan 2024 | Marinus Pharmaceuticals | SEC FORM 4 Code A | —4,600 at $0.00 | filing |
| 16 Jan 2024filed 18 Jan 2024 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,400 at $0.00 | filing |
| 8 Jun 2023filed 9 Jun 2023 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 16 May 2023filed 17 May 2023 | Marinus Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —32,400 at $0.00 | filing |
| 16 May 2023filed 17 May 2023 | Marinus Pharmaceuticals | SEC FORM 4 Code A | —7,200 at $0.00 | filing |
| 16 Jan 2023filed 18 Jan 2023 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 26 May 2022filed 27 May 2022 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 12 May 2022filed 16 May 2022 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
News
Protagonist Therapeutics (NASDAQ:PTGX) Downgraded by Wall Street Zen to BuyPTGX · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Sarah B. Noonberg; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.